Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Gilead Japan Chief Disappointed by WHO’s Recommendation Against Veklury; Label Expansion Eyed for Moderately Ill Patients
December 18, 2020
- Opdivo/Yervoy Combo Approved for First-Line NSCLC Treatment in South Korea: Ono
December 18, 2020
- Taiho Gains Non-Exclusive Rights to Use PeptiDream’s Drug Discovery Platform
December 18, 2020
- Lenvima/Keytruda Pair Hits Survival Goal in Advanced Endometrial Cancer
December 17, 2020
- Kobayashi Kako Manually Managed Itraconazole Production; Hand-Written Record on Rilmazafone Mix-Up Found
December 17, 2020
- Takeda’s Eosinophilic Esophagitis Med Gets Priority Review in US
December 17, 2020
- Daiichi Sankyo CEO Says Lead ADC Projects on Track, Eager to Boost Portfolio
December 17, 2020
- Shionogi Kicks Off Japan PI/PII Study of COVID-19 Vaccine Candidate
December 17, 2020
- Industry Sees Flip-Flops on Supplies of Kobayashi Kako-Made Products
December 16, 2020
- UCB Japan to Independently Market New Products; Stand-Alone E Keppra Sales “Going Smoothly”: President
December 16, 2020
- MSD’s Zerbaxa Being Recalled, Shipments Halted after It Fails Sterility Testing
December 16, 2020
- Lorbrena Filed as 1st Line Therapy for ALK-Positive Lung Cancer: Pfizer
December 16, 2020
- PIII Trial Launched for DS-1062 in NSCLC: Daiichi Sankyo/AZ
December 16, 2020
- Efient Filed for Label Expansion to Prevent Ischemic Stroke Recurrences
December 16, 2020
- Ono Licenses MALT1 Inhibitor for Blood Cancer Treatments from Takeda Spin-Off Chordia
December 16, 2020
- Filing for SanBio’s Sakigake Cell Therapy for TBI Likely to Be Delayed
December 16, 2020
- Solasia’s Peripheral Neuropathy Drug Fails in PIII in Colorectal Cancer Patients
December 16, 2020
- Pfizer, Life Data Initiative, NTT Data Tie Up on Big Data Research on Cancer Outcome Evaluation
December 15, 2020
- Enhertu Gets CHMP Backing for HER2-Positive Breast Cancer
December 15, 2020
- Kobayashi Kako Temporary Halts Shipments of All Products after Tainted Itraconazole Issue
December 15, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…